Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.
Type de document :
Article dans une revue
Annals of Oncology, Oxford University Press (OUP), 2010, 21 (12), pp.2305-15. 〈10.1093/annonc/mdq122〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00484825
Contributeur : Philippe Saas <>
Soumis le : mercredi 19 mai 2010 - 11:54:14
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

Identifiants

Collections

Citation

Arlene Chan, D. W. Miles, Xavier Pivot. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.. Annals of Oncology, Oxford University Press (OUP), 2010, 21 (12), pp.2305-15. 〈10.1093/annonc/mdq122〉. 〈inserm-00484825〉

Partager

Métriques

Consultations de la notice

77